In the WHAT HEALTH !? newsletter, find the latest news that has made the buzz, cutting-edge trends and groundbreaking innovations in the digital health field.
Debiopharm is taking a new step in its commitment to medical innovation. With an investment of 50 million Swiss francs to expand its Lausanne site, the Swiss company is boosting its capacity to develop new treatments in oncology and next-generation antibiotics. This project, designed to accommodate up to 300 employees by 2026, is part of a vision focused on cutting-edge healthcare and flexible workspaces.
Discover how this investment will enable Debiopharm to multiply its research programs and accelerate the development of tomorrow’s therapies.
➡️ Keep up with the latest medical breakthroughs and healthcare trends with your weekly update.
